Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.
Adenocarcinoma of the Stomach|Adenocarcinoma of the Gastroesophageal Junction
COMBINATION_PRODUCT: Regorafenib and Irinotecan|DRUG: Irinotecan
To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of overall survival (OS), Time duration from randomisation to time of death of any cause. If a patient is alive at the database cut-off date, then the patient will be censored at the last date of follow-up., expected duration of 10 months from randomisation
To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the overall survival rate, Overall survival rates at 6 and 12 months, 6 and 12 months from randomisation|To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the progression-free survival (PFS), Time duration from randomisation to time of first event (locoregional or distant relapse or progression, second malignancy, death from any cause)., expected duration of 6 months from randomisation|To evaluate the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the progression-free survival rate, Progression-free survival rates at 6 and 12 months, 6 and 12 months from randomisation|To evaluate the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the disease control rate (DCR), Percentage of patients with complete response, partial response or stable disease as best response at the database cut-off date, expected duration of 6 months from randomisation|To evaluate the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the objective response rate (ORR), Percentage of patients with complete response or partial response, expected duration of 6 months from randomisation|To compare treatment-related toxicity, Frequency and severity of adverse events assessed by NCI-CTCAE v5.0, expected 30 days after last study treatment administration|To compare the effect of treatment on quality of life, Evaluation of quality of life with EORTC quality of life questionnaire for cancer patients (QLQ-C30), expected 30 days after last study treatment administration|To compare the effect of treatment on quality of life related to gastro-oesophageal cancer, Evaluation of quality of life with EORTC quality of life specific questionnaire for gastro-oesophageal tumours (QLQ-OG25), expected 30 days after last study treatment administration
Comparative interventional prospective phase 2, randomised, open-label, multicentric trial comparing the combination of regorafenib and irinotecan (REGIRI) to irinotecan alone (IRI) as second line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.